▲ +17.43% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Stratec in the last 3 months. The average price target is €128.00, with a high forecast of €151.00 and a low forecast of €102.00. The average price target represents a 17.43% upside from the last price of €109.00.
The current consensus among 4 polled investment analysts is to hold stock in Stratec. This rating has held steady since August 2019, when it changed from a Buy consensus rating.
STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates in three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. STRATEC SE also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to STRATEC SE in December 2018. STRATEC SE was founded in 1979 and is headquartered in Birkenfeld, Germany.